Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Eduardo Roditi, ASCRS 22: Topical timolol 0.25% to enhance preoperative reference vessels image in digitally assisted intraoperative axis alignment for toric IOL

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 16th 2022

When capturing a scleral image in the biometry occasionally an error message can appear as “not enough vessels near the limbus have been found”, in consequence, using the intraoperative toric axis assistant is not possible. Timolol 0.25% is a common and available non-selective beta-adrenergic blocker. The use of topical timolol 0.25% drops as an effective method to enhance preoperative limbal vessels reference image is discussed in this touchOPHTHALMOLOGY interview with Dr Eduardo Roditi (Westmead Hospital, Sydney, Australia) as well as the clinical implications of these findings, and what further study is needed.

The presentation entitled ‘Topical Timolol 0.25% to Enhance Preoperative Reference Vessels Image in Digitally Assisted Intraoperative Axis Alignment for Toric IOL’ was presented at the American Society of Cataract and Refractive Surgery, April 22-26, 2022

Dr Eduardo Roditi won the first prize in the ASCRS 2022 film awards in home production.

Questions:

  1. What are the challenges of identification of limbal vessels in intraoperative digital axis alignment?
  2. What is the rationale for using timolol 0.25% drops to enhance preoperative limbal vessels?
  3. Could you tell us about the case study you are reporting?
  4. What are the clinical implications of these findings, and what further study is needed?

Disclosures: Eduardo Roditi has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the virtual ASCRS 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup